Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on BMS-986224 PK in Healthy Subjects
NCT03563950Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986224 in heart failure (HF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration of BMS-986224 at 5 days and Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of BMS-986224 at 5 days. Started Jun 2018; status: completed.
02
Drugs
BMS-986224
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03563950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563950.